2-(2-aminoethylamino)-5-aminocarbonylpyridine | 202460-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-aminoethylamino)-5-aminocarbonylpyridine
• 英文别名: 6-[(2-Aminoethyl)amino]pyridine-3-carboxamide；6-(2-aminoethylamino)pyridine-3-carboxamide
• CAS: 202460-47-7
• 化学式: C₈H₁₂N₄O
• 分子量: 180.209
• InChiKey: XFGLYIPLMNGCPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4S)-1-(bromoacetyl)-4-fluoropyrrolidine-2-carbonitrile 、 2-(2-aminoethylamino)-5-aminocarbonylpyridine 生成 (2S,4S)-1-[N-(tert-butoxycarbonyl)-2-[(5-aminocarbonylpyridin-2-yl)amino]ethylamino]acetyl-2-cyano-4-fluoropyrrolidine
  参考文献：
  名称：

  EP1333025

  摘要：

  公开号：

文献信息

• Synthesis and structure–activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
  作者：Hiroshi Fukushima、Akira Hiratate、Masato Takahashi、Ayako Mikami、Masako Saito-Hori、Eiji Munetomo、Kiyokazu Kitano、Sumi Chonan、Hidetaka Saito、Akio Suzuki

  DOI：10.1016/j.bmc.2008.01.016

  日期：2008.4.1

  Dipeptidyl peptidase IV (DPP-IV) inhibitors are promising antidiabetic drugs, and several drugs are in the developmental stage. We previously reported that the introduction of fluorine to the 4-position of 2-cyanopyrrolidine enhanced the DPP-IV inhibitory effect. In the present report, we examined the structure-activity relationship (SAR) of 2-cyano-4-fluoropyrrolidine with N-substituted glycine at

  二肽基肽酶IV（DPP-IV）抑制剂是有前途的抗糖尿病药物，并且几种药物都处于开发阶段。我们先前曾报道，将氟引入2-氰基吡咯烷的4-位可增强DPP-IV的抑制作用。在本报告中，我们研究了2-氰基-4-氟吡咯烷与1位上的N-取代甘氨酸的结构-活性关系（SAR）。我们报告鉴定出具有长期持续的血浆药物浓度和有效的降血糖活性的有效和稳定的DPP-IV抑制剂（TS-021）。
• Cyanopyrrolidine derivatives
  申请人：——

  公开号：US20040072892A1

  公开（公告）日：2004-04-15

  A cyanopyrrolidine derivative represented by Formula (1): 1 [wherein R 1 is a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 1 and R 2 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, R 3 and R 4 are each a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 3 and R 4 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, X is an oxygen atom or a sulfur atom, Y is —CR 5 R 6 — (wherein R 5 and R 6 are the same or different, and are each a hydrogen atom, a halogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms or an optionally substituted alkenyl group having 2 to 10 carbon atoms), or —CR 7 R 8 —CR 9 R 10 — (wherein R 7 , R 8 , R 9 and R 10 are the same or different, and each a hydrogen atom, a halogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or R 7 and R 9 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl group having 3 to 8 carbon atoms, an optionally substituted cycloalkenyl group having 4 to 8 carbon atoms, an optionally substituted bicycloalkyl group having 5 to 10 carbon atoms, or an optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms) and Z is a hydrogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or Y and Z together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group having 2 to 10 carbon atoms], or a pharmaceutically acceptable salt thereof.

  一种由式（1）表示的氰基吡咯烷衍生物：1［其中R1是卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，R2是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R1和R2一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，R3和R4分别是氢原子，卤素原子，羟基，具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基，或R3和R4一起形成氧代，羟肟基，具有1至5个碳原子的烷氧肟基或具有1至5个碳原子的烷基亚甲基，X是氧原子或硫原子，Y是- CR5R6-（其中R5和R6相同或不同，且均为氢原子，卤素原子，具有1至10个碳原子的可选取代烷基或具有2至10个碳原子的可选取代烯基），或-CR7R8-CR9R10-（其中R7，R8，R9和R10相同或不同，且均为氢原子，卤素原子或具有1至10个碳原子的可选取代烷基，或R7和R9与它们附着的碳原子一起形成具有3至8个碳原子的可选取代环烷基，具有4至8个碳原子的可选取代环烯基，具有5至10个碳原子的可选取代双环烷基或具有5至10个碳原子的可选取代双环烯基），Z是氢原子或具有1至10个碳原子的可选取代烷基，或Y和Z与它们附着的氮原子一起形成具有2至10个碳原子的可选取代环氨基，或其药学上可接受的盐。
• CYANOPYRROLIDINE DERIVATIVES
  申请人：Fukushima Hiroshi

  公开号：US20070112059A1

  公开（公告）日：2007-05-17

  Cyanopyrrolidine compound represented by Formula (1): Wherein the substituents are as defined herein. The compounds inhibit dipeptidyl peptidase IV.

  公式（1）所代表的是Cyanopyrrolidine化合物：其中取代基如本文所定义。这些化合物抑制二肽基肽酶IV。
• [EN] PHENOXYPROPANOLAMINES HAVING beta 3-ADRENERGIC ANTAGONIST ACTIVITY<br/>[FR] PHENOXYPROPANOLAMINES A ACTION ANTAGONISTE beta 3-ADRENERGIQUE
  申请人：SANOFI

  公开号：WO1998003485A1

  公开（公告）日：1998-01-29

  (EN) Phenoxypropanolamines of formula (I), wherein R1 is a C3-7 alkyl group or a C3-7 cycloalkyl group, R2 is hydrogen or an electron accepting group, and Alk is a C2-3 alkylene group having $g(b)3-adrenergic receptor antagonist activity, salts thereof, a method for preparing same, pharmaceutical compositions containing such compounds, and synthesis intermediates therefor, are disclosed.(FR) La présente invention concerne des phénoxypropanolamines de formule (I) dans laquelle R1 représente un groupe (C3-C7)-alkyle ou un groupe (C3-C7)-cycloalkyle; R2 représente l'hydrogène ou un groupe capteur d'électrons; Alk représente un groupe (C2-C3)-alkylène, à action antagoniste sur le récepteur $g(b)3-adrénergique, leurs sels, un procédé pour leur préparation, des compositions pharmaceutiques en contenant et des intermédiaires de synthèse.
• EP1333025
  申请人：——

  公开号：——

  公开（公告）日：——